Head and Neck Cancer Drugs/Therapeutics Market Size, Share & Trends Analysis Report By Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), By Region, And Segment Forecasts, 2016 - 2022

Published: Mar, 2018 | Pages: 79 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global head and neck cancer drugs market size is expected to be valued at USD 1.41 billion by 2022, as per a new report by Grand View Research, Inc., registering a CAGR of 9.4% during the forecast period. The market is expected to be collectively driven by development of innovative and cost-effective treatments, numerous side effects related to radiation therapy and chemotherapy, increased healthcare expenditure, and better government initiatives.

As most patients suffering from head and neck cancer are diagnosed at an advanced stage, their management is often done with a multidisciplinary approach involving surgery, radiation therapy, chemotherapy, and immunotherapy in the head and neck cancer therapeutics market. Major challenges faced by this patient population are morbidity issues and poor quality of life owing to the incapacitating effects of standard of care treatment paradigms. Anemia, diarrhea, nausea, vomiting, joint pain, and osteoporosis are some of the main side effects resulting from head and neck cancer treatments.

Based on recent clinical results, immunotherapies have gained traction as a precision medicine initiative for the management of head and neck cancer. Increased immunity and immune modulation research in cancer offers new vulnerabilities that may be pharmacologically exploitable. Immunotherapy drugs such as PD inhibitors, Opdivo, and Keytruda have shown superior safety and efficacy profile in treatment of head and neck cancer. Expansion of immunotherapies will continue moving toward rational combinations with other first line or adjuvant therapies for effective treatment of metastatic or recurrent head and neck cancer. EGFR and microtubule inhibitor therapeutic classes are witnessing a fundamental shift from biologics to biosimilars.

Further key findings from the report suggest:

• Market growth will be driven by rising number of patients, increasing adoption of immunotherapeutic drugs, and launch of new drug delivery approaches to improve overall survival rates

• Among EU5, Germany captured the top position in the global head and neck cancer therapeutics market, whereas by 2022, Spain is expected to lead the market. U.S. is expected to witness the fastest growth over the forecast period

• Immune checkpoint inhibitors such as Opdivo and Keytruda are gaining traction and will continue to do so through forecast period, capturing more than 60.0% of the market in 2022

• PD inhibitors will capture market share from microtubule inhibitors and EGFR inhibitors but will help expand overall franchise revenue

• Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with superior safety profile

• Late stage pipeline products include checkpoint inhibitors such as Imfinzi and Bavencio

• Key players operating in this industry include Bristol-Myers Squibb, Merck, Eli Lilly, and Sanofi.

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information procurement
                 1.2 Information or Data Analysis
                     1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology
                 3.1 Disease Primer
                     3.1.1 Types:
                         3.1.1.1 Oral and Oropharyngeal Cancer
                         3.1.1.2 Laryngeal and Hypopharyngeal Cancer
                         3.1.1.3 Nasopharyngeal Cancer
                         3.1.1.4 Nasal Cavity and Paranasal Sinus Cancer
                         3.1.1.5 Salivary Gland Cancer
                 3.2 Epidemiology by Indications
                     3.2.1 Oral Cavity Cancers
                     3.2.2 Oropharyngeal Cancers
                     3.2.3 Lip Cancers
                     3.2.4 Salivary Gland Cancers
                     3.2.5 Nasopharyngeal Cancers
                     3.2.6 Hypopharyngeal Cancers
                 3.3 Current Prevalence Rate and Numbers for Seven Major Markets (U.S., Japan, EU5)
                 3.4 Current Incidence Rate and Numbers for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Head and Neck Cancer Drugs Market Overview
                 4.1 Market by Treatment
                     4.1.1 Surgery
                     4.1.2 Radiation Therapy
                     4.1.3 Chemotherapy
                     4.1.4 Immunotherapy
                 4.2 Market by Therapeutic Class
                     4.2.1 PD Inhibitors
                     4.2.2 EGFR Inhibitors
                     4.2.3 Microtubule Inhibitors
                 4.3 Market Size & Forecast
                 4.4 Sales Performance
                     4.4.1 Sales Performance, by Drug Class (2016 - 2022)
                     4.4.2 Sales Performance, by Region (2016 - 2022)
                     4.4.3 Sales Performance, by Company (2016 - 2022)
                 4.5 Market Share Distribution
                 4.6 Market Dynamics among Leading Brands
                 4.7 Patent Expiry Schedule
                 4.8 Drivers and Challenges
                     4.8.1 Drivers
                     4.8.2 Challenges
                 4.9 M&A, Deal Landscape (2013-2017 YTD)
                 4.10 Pricing and Reimbursement
                 4.11 Biosimilar Evolution
                 4.12 Emerging Markets
                 4.13 SWOT

Chapter 5 Head and Neck Cancer Drugs Market: Pipeline Intelligence
                 5.1 Pipeline Landscape
                     5.1.1 Leading Drugs in Development
                     5.1.2 Key R&D Trends
                 5.2 Promising Drug Candidates in Pipeline
                     5.2.1 Late Stage Pipeline Analysis
                     5.2.2 Profile of Disruptive Drugs
                         5.2.2.1 Opdivo (nivolumab)
                         5.2.2.2 Keytruda (pembrolizumab)
                         5.2.2.3 Imfinzi (durvalumab)
                         5.2.2.4 Bavencio (avelumab)
                         5.2.2.5 Yervoy (ipilimumab)
                         5.2.2.6 Tremelimumab
                         5.2.2.7 Buparlisib
                         5.2.2.8 Epacadostat
                 5.3 Global Pipeline Forecast

Chapter 6 Competitive Landscape
                 6.1 Bristol-Myers Squibb
                     6.1.1 Company Overview
                     6.1.2 Current Product Portfolio
                     6.1.3 Product Forecast Sales up to 2022
                     6.1.4 Strategic Initiatives (Bristol-Myers Squibb)
                         6.1.4.1 Key Company News Flow
                     6.1.5 Pipeline Analysis & Overview
                     6.1.6 Catalysts & Events Calendar
                     6.1.7 SWOT
                 6.2 Merck
                     6.2.1 Company Overview
                     6.2.2 Current Product Portfolio
                     6.2.3 Product Forecast Sales up to 2022
                     6.2.4 Strategic Initiatives (Merck)
                         6.2.4.1 Key Company News Flow
                     6.2.5 Pipeline Analysis & Overview
                     6.2.6 Catalysts & Events Calendar
                     6.2.7 SWOT
                 6.3 Sanofi
                     6.3.1 Company Overview
                     6.3.2 Current Product Portfolio
                     6.3.3 Product Forecast Sales up to 2022
                     6.3.4 Strategic Initiatives (Sanofi)
                         6.3.4.1 Key Company News Flow
                     6.3.5 Pipeline Analysis & Overview
                     6.3.6 Catalysts & Events Calendar
                     6.3.7 SWOT
                 6.4 Eli Lilly
                     6.4.1 Company Overview
                     6.4.2 Current Product Portfolio
                     6.4.3 Product Forecast Sales up to 2022
                     6.4.4 Strategic Initiatives (Eli Lilly)
                         6.4.4.1 Key Company News Flow
                     6.4.5 Pipeline Analysis & Overview
                     6.4.6 Catalysts & Events Calendar
                     6.4.7 SWOT

Chapter 7 Market Outlook
                 7.1 What the Future Holds
                 7.2 Winners and Losers
                     7.2.1 Winners
                     7.2.2 Losers
                 7.3 Emerging Companies
                 7.4 The Road Ahead

List of Tables

TABLE 1 Current Prevalence Rate and Numbers across Seven Major Markets - 2015
TABLE 2 Current Incidence Rates and Numbers across Seven Major Markets - 2016
TABLE 3 Sales Performance, by Drug Class (in USD Million)
TABLE 4 Sales Performance, by Region (in USD Million)
TABLE 5 U.S. Sales by Therapeutic Class (in USD Million)
TABLE 6 Japan Sales by Therapeutic Class (in USD Million)
TABLE 7 U.K. Sales by Therapeutic Class (in USD Million)
TABLE 8 Germany Sales by Therapeutic Class (in USD Million)
TABLE 9 Spain Sales by Therapeutic Class (in USD Million)
TABLE 10 France Sales by Therapeutic Class (in USD Million)
TABLE 11 Italy Sales by Therapeutic Class (in USD Million)
TABLE 12 Sales Performance, by Company (in USD Million)
TABLE 13 Patent Expiry Schedule
TABLE 14 Taxotere (Docetaxel) Biosimilars
TABLE 15 Erbitux (Cetuximab) Biosimilars in Pipeline
TABLE 16 R&D Pipeline Overview
TABLE 17 Other Drugs in Pipeline
TABLE 18 Late Stage Pipeline
TABLE 19 Product Profile: Opdivo (nivolumab)
TABLE 20 Product Profile: Keytruda (pembrolizumab)
TABLE 21 Product Profile: Imfinzi (durvalumab)
TABLE 22 Product Profile: Bavencio (avelumab)
TABLE 23 Product Profile: Yervoy (ipilimumab)
TABLE 24 Product Profile: Tremelimumab
TABLE 25 Product Profile: Buparlisib
TABLE 26 Product Profile: Epacadostat
TABLE 27 Global Pipeline Forecast
TABLE 28 Product Portfolio: Opdivo
TABLE 29 Opdivo Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 30 Bristol-Myers Squibb Pipeline
TABLE 31 Events Calendar
TABLE 32 Product Portfolio: Keytruda
TABLE 33 Keytruda Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 34 Merck Pipeline
TABLE 35 Events Calendar
TABLE 36 Product Portfolio: Taxotere
TABLE 37 Taxotere Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 38 Sanofi Pipeline
TABLE 39 Events Calendar
TABLE 40 Product Portfolio: Erbitux
TABLE 41 Erbitux Sales Forecast, 2016 - 2022 (in USD Million)
TABLE 42 Eli Lilly Pipeline
TABLE 43 Events Calendar

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 5-year Limited Duration Prevalence across Seven Major Markets - 2015
FIG. 8 5-year Limited Duration Prevalence Rates across Seven Major Markets - 2015
FIG. 9 Gender Specific Prevalence across Seven Major Markets - 2015
FIG. 10 Gender Specific Prevalence Rates across Seven Major Markets - 2015
FIG. 11 Current Incidence by Numbers for Seven Major Markets - 2014
FIG. 12 Current Incidence Rates per 100,000 in Seven Major Markets - 2014
FIG. 13 Gender Specific Incidence by Numbers across Seven Major Markets - 2014
FIG. 14 Gender Specific Incidence Rates per 100,000 across Seven Major Markets - 2014
FIG. 15 Head and Neck Cancer Drugs Market Forecast (2016, 2022)
FIG. 16 Head and Neck Cancer Drugs Market by Therapeutic Class (2016, 2022)
FIG. 17 Head and Neck Cancer Drugs Market by Region (2016, 2022)
FIG. 18 Market Share Distribution (2016, 2022)
FIG. 19 Head and Neck Cancer Drugs Market SWOT
FIG. 20 Bristol Myers Squibb SWOT Analysis
FIG. 21 Merck SWOT Analysis
FIG. 22 Sanofi SWOT Analysis
FIG. 23 Eli Lilly SWOT Analysis